Cytomegalovirus infection of the central nervous system

Herpes

Volumn 11, Issue SUPPL. 2, 2004, Pages

  Griffiths, Paul ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Central nervous system; Cytomegalovirus; Encephalitis; Guillain barr syndrome; Therapy management recommendations

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; DRUG DERIVATIVE; GANCICLOVIR; VALGANCICLOVIR;

CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID; CYTOMEGALIC INCLUSION BODY DISEASE; CYTOMEGALOVIRUS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; PATHOLOGY; PRACTICE GUIDELINE; REVIEW;

ACYCLOVIR; ANTIVIRAL AGENTS; CENTRAL NERVOUS SYSTEM VIRAL DISEASES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; INFUSIONS, INTRAVENOUS; PRACTICE GUIDELINES;

EID: 4344629112     PISSN: 09697667     EISSN: 14701537     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (83)

1. Pillay D, Griffiths PD. Diagnosis of cytomegalovirus infection: a review. Genetourin Med 1992; 68:183-188.
2. Collier AC, Meyers JD, Corey L, Murphy VL, Roberts PL, Handsfield HH. Cytomegalovirus infection in homosexual men. Relationship to sexual practices, antibody to human immunodeficiency virus, and cell-mediated immunity. Am J Med 1987;82: 593-601.
3. Drew WL, Miner RC, Busch DF, Follansbee SE, Gullett J, Mehalko SG et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1991; 163:716-719.
4. McCutchan JA. Cytomegalovirus infections of the nervous system in patients with AIDS. Clin Infect Dis 1995;20:747-754.
5. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE. Incidence and natural history of cyotomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis 1992; 166:1223-1227.
6. Hoover DR, Saah AJ, Bacellar H, Phair J, Detels R, Anderson R et al. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study. N Engl J Med 1993; 329:1922-1926.
7. Palella FJ, Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1988;338:853-860.
8. Gonzales MF, Davis RL. Neuropathology of acquired immunodeficiency syndrome. Neuropathol Appl Neurobiol 1988;14:345-363.
9. Arribas JR, Storch GA, Clifford DB, Tselis AC. Cytomegalovirus encephalitis. Ann Intern Med 1996;125:577-587.
10. Behar R, Wiley C, McCutchan JA. Cytomegalovirus polyradiculoneuropathy in acquired immune deficiency syndrome. Neurology 1987; 37:557-561.
11. Miller RF, Fox JD, Thomas P, Waite JC, Sharvell Y, Gazzard BG et al. Acute lumbosacral polyradiculopathy due to cytomegalovirus in advanced HIV disease: CSF findings in 17 patients. J Neurol Neurosurg Psychiatry 1996;61:456-460.
12. So YT, Olney RK. Acute lumbosacral polyradiculopathy in acquired immunodeficiency syndrome: experience in 23 patients. Ann Neurol 1994;35:53-58.
13. Roullet E, Assuerus V, Gozlan J, Ropert A, Said G, Baudrimont M et al. Cytomegalovirus multifocal neuropathy in AIDS: analysis of 15 consecutive cases. Neurology 1994;44:2174-2182.
14. Said G, Lacroix C, Chemouilli P, Goulon-Goeau C, Roullet E, Penaud D et al. Cytomegalovirus neuropathy in acquired immunodeficiency syndrome: a clinical and pathological study. Ann Neurol 1991; 29:139-146.
15. Delia S. Diagnosis and management of CMV-associated neurological manifestations in HIV infection. Herpes 1997;4: 68-71.
16. Vinters HV, Kwok MK, Ho HW, Anders KH, Tomiyasu U, Wolfson WL et al. Cytomegalovirus in the nervous system of patient with the acquired immune deficiency syndrome. Brain 1989;112: 245-268.
17. Fiala M, Singer BJ, Graves MC, Tourtellotte WW, Stewart JA, Schable CA et al. AIDS dementia complex complicated by cytomegalovirus encephalopathy. J Neurol 1993; 240:223-231.
18. Cinque P, Vago L, Dahl H, Brytting M, Terreni MR, Fornara C et al. Polymerase chain reaction on cerebrospinal fluid for diagnosis of virus-associated opportunistic diseases of the central nervous system in HIV-infected patients. AIDS 1996; 10:951-958.
19. Deayton JR, Griffiths PD. When can cytomegalovirus prophylaxis and maintenance theraphy be stopped in HIV disease? Curr Opin Infect Dis 2000;13:637-641.
20. Morgello S, Cho ES, Nielsen S, Devinsky O, Petito CK. Cytomegalovirus encephalitis in patients with acquired immunodeficiency syndrome: an autopsy study of 30 cases and a review of the literature. Hum Pathol 1987;18:289-297.
21. Brantsaeter AB, Liestol K, Goplen AK, Dunlop O, Bruun JN. CMV disease in AIDS patients: incidence of CMV disease and relation to survival in a population-based study from Oslo. Scand J Infect Dis 2002; 34:50-55.
22. McCutchan JA, Freeman W, Eisenman P. Does subclinical CMV encephalitis cause neuropsychological dysfunction in AIDS patients presenting with CMV retinitis? National Conference on Human Retroviruses, Washington, DC, January 29 - February 02, 1995.
23. Holland NR, Power C, Matthew VP, Glass JD, Forman M, McArthur JC. Cytomegalovirus encephalitis in acquired immunodeficiency syndrome (AIDS). Neurology 1994;44: 507-514.
24. Roullet E. Opportunistic infections of the central nervous system during HIV-1 infection (emphasis on cytomegalovirus disease). J Neurol 1999;246: 237-243.
25. Singh N, Anderegg KA, Yu VL. Significance of hypoglycorrhachia in patients with AIDS and cytomegalovirus meningoencephalitis. Clin Infect Dis 1993;17:283-284.
26. Gozlan J, Salord JM, Roullet E, Baudrimont M, Caburet F, Picard O et al. Rapid detection of cytomegalovirus DNA in cerebrospinal fluid of AIDS patients with neurologic disorders. J Infect Dis 1992; 166:1416-1421.
27. Gozlan J, el Amrani M, Baudrimont M, Costagliola D, Salord JM, Duvivier C et al. A prospective evaluation of clinical criteria and polymerase chain reaction assay of cerebrospinal fluid for the diagnosis of cytomegalovirus-related neurological diseases during AIDS. AIDS 1995;9: 253-260.
28. Nagamitsu S, Okabayashi S, Dai S, Morimitsu Y, Murakami T, Matsuishi T et al. Neuroimaging and neuropathologic findings in AIDS patient with cytomegalovirus infection. Intern Med 1994;33:158-162.
29. Clifford DB, Arribas JR, Storch GA, Tourtellote W, Wippold FJ. Magnetic resonance brain imaging lacks sensitivity for AIDS associated cytomegalovirus encephalitis. J Neurovirol 1996;2:397-403.
30. Cinque P, Cleator GM, Weber T, Monteyne P, Sindic C, Gerna G et al. Diagnosis and clinical management of neurological disorders cuased by cytomegalovirus in AIDS patients. European Union Concerted Action on Virus Meningitis and Encephalitis. J Neurovirol 1998; 4:120-132.
31. Wolf DG, Spector SA. Diagnosis of human cytomegalovirus central nervous system disease in AIDS patients by DNA amplification from cerebrospinal fluid. J Infect Dis 1992;166:1412-1415.
32. Cinque P, Vago L, Brytting M, Castagna A, Accordini A, Sundqvist VA et al. Cytomegalovirus infection of the central nervous system in patients with AIDS: diagnosis by DNA amplification from cerebrospinal fluid. J Infect Dis 1992;166:1408-1411.
33. Shinkai M, Bozzette SA, Powderly W, Frame P, Spector SA. Utility of urine and leukocyte cultures and plasma DNA polymerase chain reaction for identification of AIDS patients at risk for developing human cytomegalovirus disease. J Infect Dis 1997;175: 302-308.
34. Dodt KK, Jacobsen PH, Hofmann B, Meyer C, Kolmos HJ, Skinhoj P et al. Development of cytomegalovirus (CMV) disease may be predicted in HIV-infected patients by CMV polymerase chain reaction and the antigenemia test. AIDS 1997; 11:F21-26.
35. Bowen EF, Sabin CA, Wilson P, Griffiths PD, Davey CC, Johnson MA et al. Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease. AIDS 1997;11:889-893.
36. Fox JD, Brink N, Zuckerman M, Neild P, Gazzard BG, Tedder RS et al. Detection of herpesvirus DNA by nested polymerase chain reaction in cerebrospinal fluid of human immunodeficiency virus-infected persons with neurologic disease: a prospective evaluation. J Infect Dis 1995;172:1087-1090.
37. Cinque P, Baldanti F, Vago L, Terreni MR, Lillo F, Furione M et al. Ganciclovir therapy for cytomegalovirus (CMV) infection of the central nervous system in AIDS patients: monitoring by CMV DNA detection cerebrospinal fluid. J Infect Dis 1995;171:1603-1606.
38. Arribas JR, Clifford DB, Fichtenbaum CJ, Commins DL, Powderly WG, Storch GA. Level of cytomegalovirus (CMV) DNA in cerebrospinal fluid of subjects with AIDS and CMV infection of the central nervous system. J Infect Dis 1995;172:527-531.
39. Shinkai M, Spector SA. Quantitation of human cytomegalovirus (HCMV) DNA in cerebrospinal fluid by competitive PCR in AIDS patients with different HCMV central nervous system dsiease. Scan J Infect Dis 1995;27: 559-561.
40. Cohen BA. Prognosis and response to therapy of cytomegalovirus encephalitis and meningomyelitis in AIDS. Neurology 1996; 46:444-450.
41. Bylsma SS, Achim CL, Wiley CA, Gonzalez C, Kuppermann BD, Berry C et al. The predictive value of cytomegalovirus retinitis for cytomegalovirus encephalitis in acquired immunodeficiency syndrome. Arch Opthalmol 1995;113: 89-95.
42. Fuller GN. Cytomegalovirus and the peripheral nervous system in AIDS. J Acquir Immune Defic Syndr 1992;5:S33-36.
43. Winer JB, Hughes RA, Anderson MJ, Jones DM, Kangro H, Watkins RP. A prospective study of acute idiopathic neuropathy, II. Antecedent events. J Neurol Neurosurg Psychiatry 1988;51: 613-618.
44. Jacobs BC, Rothbarth PH, van der Meche FG, Herbrink P, Schmitz PI, de Klerk MA et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology 1998;51:1110-1115.
45. Schmitz H, Enders G. Cytomegalovirus as a frequent cause of Guillain-Barré syndrome. J Med Virol 1977;1: 21-27.
46. Dowling PC, Cook SD. Role of infection in Guillain-Barré syndrome: laboratory confirmation of herpesviruses in 41 cases. Ann Neurol 1981;9: 44-55.
47. Visser LH, van der Meche FG, Meulstee J, Rothbarth PP, Jacobs BC, Schmitz PI et al. Cytomegalovirus infection and Guillain-Barré syndrome: the clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barré Study Group. Neurology 1996;47:668-673.
48. Boivin G, Chou S, Quirk MR, Erice A, Jordan MC. Detection of ganciclovir resistance mutations quantitation of cytomegalovirus (CMV) DNA in leukocytes of patients with fatal disseminated CMV disease. J Infect Dis 1996;173:523-528.
49. Yuki N. Infectious origins of, and molecular mimicry in, Gulllain-Barré and Fisher syndromes. Lancet Infect Dis 2001; 1:29-37.
50. Berman SM, Kim RC. The development of cytomegalovirus encephalitis in AIDS patients receiving ganciclovir. Am J Med 1994;96: 415-419.
51. Hengge UR, Brockmeyer NH, Malessa R, Ravens U, Goos M. Foscarnet penetrates the blood-brain barrier: rationale for therapy of cytomegalovirus encephalitis. Antimicrob Agents Chemother 1993; 37:1010-1014.
52. Cooper DA, Pehrson PO, Pedersen C, Moroni M, Oksenhendler E, Rozenbaum W et al. The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind randomized trial. European-Australian Collaborative Group. AIDS 1993;7:197-207.
53. Youle MS, Gazzard BG, Johnson MA, Cooper DA, Hoy JF, Busch H et al. Effects of high-dose oral acyclovir on herpesvirus disease and survival in patients with advanced HIV disease: a double-blind, placebo-controlled study. European-Australian Acyclovir Study Group. AIDS 1994;8:641-649.
54. Spector SA, McKinley GF, Lalezari JP, Samo T, Andruczk R, Follansbee S et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. N Engl J Med 1996;334:1491-1497.
55. Feinberg JE, Hurwitz S, Cooper D, Sattler FR, MacGregor RR, Powderly W et al. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. J Infect Dis 1998;177:48-56.
56. Cocohoba JM, McNicholl IR. Valganciclovir: an advance in cytomegalovirus therapeutics. Ann Pharmacother 2002;36: 1075-1079.
57. Martin DF, Sierra-Madero J, Walmsley S, Wolitz RA, Macey K, Georgiou P et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002;346: 1119-1126.
58. Bell WR, Chulay JD, Feinberg JE, Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine (Baltimore) 1997;76: 369-380.
59. Maslo C, Peraldi MN, Desenclos JC, Mougenol B, Cywiner-Golenzer C, Chatelet FP et al. Thrombotic microangiopathy and cytomegalovirus disease in patients infected with human immunodeficiency virus. Clin Infect Dis 1997;24:350-355.
60. Peters M, Timm U, Schurmann D, Pohle HD, Ruf B. Combined and alternating ganciclovir and foscarnet in acute and maintenance therapy of human immunodeficiency virus-related cytomegalovirus encephalitis refractory to ganciclovir alone. A case report and review of the literature. Clin Investig 1992; 70:456-458.
61. Anduze-Faris BM, Fillet AM, Gozlan J, Lancar R, Boukli N, Gasnault J et al. Induction and maintenance therapy of cytomegalovirus central nervous system infection in HIV-infected patients. AIDS 2000;14: 517-524.
62. Cohen BA, McArthur JC, Grohman S, Patterson B, Glass JD. Neurologic prognosis of cytomegalovirus polyradiculomyelopathy in AIDS. Neurology 1993;43: 493-499.
63. Miller RG, Storey JR, Greco CM. Ganciclovir in the treatment of progressive AIDS-related polyradiculopathy. Neurology 1990; 40:569-574.
64. Anders HJ, Weiss N, Bogner JR, Goebel FD. Ganciclovir and foscarnet efficacy in AIDS-related CMV polyradiculopathy. J Infect 1998; 36:29-33.
65. Whitley RJ, Jacobson MA, Friedberg DN, Holland GN, Jabs DA, Dieterich DT et al. Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA. Arch Intern Med 1998;158:957-969.
66. Tural C, Romeu J, Sirera G, Andreu D, Conejero M, Ruiz S et al. Long-lastng remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J Infect Dis 1998;177:1080-1083.
67. Vrabec TR, Baldassano VF, Whitcup SM. Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinis and elevated CD4+ counts. Ophthalmology 1998; 105:1259-1264.
68. Macdonald JC, Torriani FJ, Morse LS, Karavellas MP, Reed JB, Freeman WR. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. J Infect Dis 1998;177:1182-1187.
69. Jabs DA, Enger C, Dunn JP, Forman M, Hubbard L, Cytomegalovirus retinitis and viral resistance: 3. Culture results. CMV Retinitis and Viral Resistance Study Group. Am J Ophthalmol 1998; 126:543-549.
70. Kirk O, Lundgren JD, Pedersen C, Nielsen H, Gerstoft J. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy? AIDS 1999;13:1647-1651.
71. Di Perri G, Vento S, Mazzi R, Bonora S, Bonora A, Trevenzoli M et al. Recovery of long-term natural protection against reactivation of CMV retinitis in AIDS patients responding to highly active antireretroviral therapy. J Infect 1999;39:193-197.
72. Whitcup SM, Fortin E, Lindblad AS, Griffiths P, Metcalf JA, Robinson MR et al. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. JAMA 1999; 282:1633-1637.
73. Mezzaroma I, Carlesimo M, Pinter E, Muratori DS, Di Sora F, Chiarotti F et al. Clinical and immunologic response without decrease in virus load in patients with AIDS after 24 months of highly active antiretroviral therapy. Clin Infect Dis 1999;29:1423-1430.
74. Soriano V, Dona C, Rodriguez-Rosado R, Barriero P, Gonzalez-Lahoz J. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 2000;14:383-386.
75. Wolf DG, Lee DJ, Spector SA. Detection of human cytomegalovirus mutations associated with ganciclovir resistance in cerebrospinal fluid of AIDS patients with central nervous system disease. Antimicrob Agents Chemother 1995;39:2552-2554.
76. Smith IL, Shinkai M, Freeman WR, Spector SA. Polyradiculopathy associated with ganciclovir-resistant cytomegalovirus in an AIDS patient: phenotypic and genotypic characterization of sequential virus isolates. J Infect Dis 1996;173:1481-1484.
77. Bowen EF, Emery VC, Wilson P, Johnson MA, Davey CC, Sabin CA et al. Cytomegalovirus Polymerase chain reaction viraemia in patients receiving ganciclovir maintenance therapy for retinitis. AIDS 1998; 12:605-611.
78. Stinski MF. Molecular basis of cytomegalovirus, In: Herpesviruses (Roizman B, ed). New York: Plenum Publishing Corp., 1983; 67-113.
79. Emergy VC, Cope AV, Bowen EF, Gor D, Griffiths PD. The dynamics of human cytomegalovirus replication in vivo. J Exp Med 1999;190: 177-182.
80. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373: 117-122.
81. Emery VC, Griffiths PD. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci U S A 2000;97:8039-8044.
82. Drew WL, Ives D, Lalezari JP, Crumpacker C, Follansbee SE, Spector SA et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group. N Engl J Med 1995;333:615-620.
83. Erice A. Resistance of human cytomegalovirus to antiviral drugs. Clin Microbiol Rev 1999;12:286-297.